Home » Largest Independent Benchmarking Survey for Operational Excellence in Pharmaceutical Manufacturing
Largest Independent Benchmarking Survey for Operational Excellence in Pharmaceutical Manufacturing
The Institute of Technology Management and the Transfer Center for Technology Management at the University of St.Gallen, Switzerland have been conducting their international benchmarking study about Operational Excellence now for seven years.
This Benchmarking currently undergoes a major re-launch. The questionnaire and corresponding personalized analysis have been improved in cooperation with leading pharmaceutical companies under supervision of Professor Dr. Thomas Friedli. Since 2004 the benchmarking has been continuously adapted to the changing environment and needs of the participating pharmaceutical companies.
The result speaks for itself: Meanwhile 181 pharmaceutical manufacturing sites of more than 80 different companies are included in the database. Thebenchmarking provides a detailed analysis for participating companies how they perform compared to competitors and how they should position their site to ensure its future. A personal report (including 50 operational KPIs) provides a means to derive the right improvement priorities for future competitiveness.
The benchmarking project follows the “International Benchmarking Code of Conduct” which ensures ethical activities of all involved parties and strict confidentiality of data. If your company or site wantsto join 2012, please do not hesitate to contact us.
For further information please visit www.opexbenchmarking.com or contact email@example.com.
Novo Acquires Xellia Pharmaceuticals for $700 MillionFrom PharmaTimes Online
Novo A/S has acquired Xellia Pharmaceuticals of Norway
Royalty Increases Bid as Elan Unveils AcquisitionsFrom PharmaTimes Online
Royalty Pharma has resurfaced to raise its bid to acquire the Irish drugmaker Elan
New Asthma Drug Offers Hope for PatientsFrom Forbes
An experimental asthma drug could give new hope to patients for whom existing medicines are not enough
Syrian Pharma Production Nearly Halted by WarFrom AFP
A shortage of foreign currency has brought production to a near halt in Syria
Camfil APC Opens Manufacturing Plant in the UKFrom Camfil
Camfil announced the grand opening of its new 40,000-sq.-ft. facility
Actavis Acquiring Warner Chilcott for $8.5BFrom AP
Actavis to buy Warner Chilcott in an all-stock transaction
Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics
NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration
Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com
Agreement creates unique strategic collaboration for development and clinical trial execution
$15 Billion Myland Offer Rejected By ActavisFrom Bloomberg.com
Actavis has rejected drugmaker Mylan Inc's cash-and-stock offer for $15 billion. They have decided to continue talks to take over Warner Chilcott Plc instead, sources have said.
Rapid Micro Biosystems Offers Workshops at New European Headquarters in MunichFrom Rapid Micro Biosystems
Company hosts hands-on demonstrations of its Growth Direct System
- All news »